In addition, the discordance rate of HER3-high scores in samples at initial diagnosis versus recurrence was 27.5% and 53.1% for ovarian and endometrial cancers, respectively (Figs. 1d, 2d). This evidence concerns the gene ERBB3 and endometrial cancer.